Andrew Protheroe
A5062742458- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Bladder and Urothelial Cancer Treatments
- Renal and related cancers
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Testicular diseases and treatments
- Radiopharmaceutical Chemistry and Applications
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Growth Hormone and Insulin-like Growth Factors
- Epigenetics and DNA Methylation
- Cancer Treatment and Pharmacology
- Cancer Research and Treatments
- Metabolism, Diabetes, and Cancer
- Sarcoma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Cancer-related Molecular Pathways
- Multiple Myeloma Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Hormonal and reproductive studies
- Sexual Differentiation and Disorders
- Ferroptosis and cancer prognosis
- Multiple and Secondary Primary Cancers
Oxford University Hospitals NHS Trust
2016-2025
University of Oxford
2016-2025
Churchill Hospital
2015-2024
Cancer Research UK Oxford Centre
2003-2023
Hospital Universitario Reina Sofía
2021
Instituto Maimónides de Investigación Biomédica de Córdoba
2021
John Radcliffe Hospital
2010-2021
National Health Service
2021
Oxford BioMedica (United Kingdom)
2020
Instituto de Oncología de Rosario
2017
Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition olaparib.
Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate with androgen-deprivation therapy in patients newly diagnosed, metastatic, castration-sensitive cancer.In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 1199 to receive either (1000 mg daily, given once daily as four 250-mg tablets) (5 daily) (the group) or...
Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial design.
High-intensity focused ultrasound (HIFU) provides a potential noninvasive alternative to conventional therapies. We report our preliminary experience from clinical trials designed evaluate the safety and feasibility of novel, extracorporeal HIFU device for treatment liver kidney tumours in Western population. The extracorporeal, ultrasound-guided Model-JC Tumor Therapy System (HAIFU™ Technology Company, China) has been used treat 30 patients according four trial protocols. Patients with...
BackgroundSTAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on outcomes stratified by burden M1 patients.MethodsWe randomly allocated in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox...
To evaluate the performance of active surveillance as a management strategy in broad populations and to inform development schedules by individual patient data regarding timing type relapse.Retrospective study including from 2,483 clinical stage I (CSI) patients, 1,139 CSI nonseminoma 1,344 seminoma managed with surveillance, majority treated between 1998 2010. Clinical outcomes relapse death, time distribution, extent method detection observed on were recorded.Relapse occurred 221 (19%)...
Adding abiraterone acetate with prednisolone (AAP) or docetaxel (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced metastatic prostate cancer: evaluation of drug efficacy: a multi-arm multi-stage platform randomised controlled protocol recruiting patients high-risk locally PCa starting long-term androgen deprivation (ADT). The provides the only direct, comparative data SOC + AAP versus DocP.
Background & AimsThe pathogenesis of immune checkpoint inhibitor (ICI)–colitis remains incompletely understood. We sought to identify key cellular drivers ICI-colitis and their similarities idiopathic ulcerative colitis, determine potential novel therapeutic targets.MethodsWe used a cross-sectional approach study patients with ICI-colitis, those receiving ICI without the development healthy controls. A subset were studied longitudinally. applied range methods, including multiparameter...
People with cancer are at increased risk of hospitalisation and death following infection SARS-CoV-2. Therefore, we aimed to conduct one the first evaluations vaccine effectiveness against breakthrough SARS-CoV-2 infections in patients a population level.
Abstract The type 1 insulin-like growth factor receptor (IGF-1R) is a transmembrane glycoprotein composed of two extracellular α subunits and β with tyrosine kinase activity. IGF-1R frequently upregulated in cancers signals from the cell surface to promote proliferation survival. Recent attention has focused on as target for cancer treatment. Here, we report that nuclei human tumor cells contain IGF-1R, detectable using multiple antibodies α- β-subunit domains. Cell-surface translocates...
REOLYSIN (Oncolytics Biotech) consists of a wild-type oncolytic reovirus, which has selective cytotoxicity for tumor cells while sparing normal cells. In phase I study as single agent, repeated infusions reovirus were safe with evidence antitumor activity. Preclinical studies indicate potential synergy between and chemotherapeutic agents. A multicenter, dose escalation was designed to assess the safety combining docetaxel chemotherapy in patients advanced cancer.Patients received 75 mg/m(2)...
5001 Background: STAMPEDE is a randomised controlled trial using novel multi-arm multi-stage design. It recruits men (pts) with high-risk locally advanced or metastatic prostate cancer (PCa) starting long-term hormone therapy (HT) for the first time. The initially assessed adding 1 2 of 3 treatment approaches to standard care (SOC). We report primary survival results research comparisons that recruited through all their intermediate analyses: docetaxel (D), zoledronic acid (ZA) & combination...
Long-term hormone therapy alone is standard care for metastatic or high-risk, non-metastatic prostate cancer. STAMPEDE--an international, open-label, randomised controlled trial--uses a novel multiarm, multistage design to assess whether the early additional use of one two drugs (docetaxel, zoledronic acid, celecoxib, acid and docetaxel, celecoxib) improves survival in men starting first-line, long-term therapy. Here, we report preplanned, second intermediate analysis comparing plus...
Abstract Papillary renal cell carcinoma (pRCC) is an important subtype of kidney cancer with a problematic pathological classification and highly variable clinical behaviour. Here we sequence the genomes or exomes 31 pRCCs, in four tumours, multi-region sequencing undertaken. We identify BAP1 , SETD2 ARID2 Nrf2 pathway genes ( KEAP1 NHE2L2 CUL3 ) as probable drivers, together at least eight other possible drivers. However, only ~10% tumours harbour detectable pathogenic changes any one...
4506 Background: Atezolizumab is a PD-L1 inhibitor which licenced in metastatic urothelial cancer. This study investigates the efficacy and safety of neoadjuvant atezolizumab given prior to cystectomy operable muscle invasive transitional cell carcinoma bladder Methods: single arm phase 2 investigated cycles (1200mg Q3) cancer (T2-4N0M0). Pathological complete response (pCR) occurring ≥20% patients was primary endpoint. Biomarker analysis on sequential tissue co-primary Cross sectional...
Abstract Background Immune checkpoint inhibitors (ICI) improve survival but cause immune-related adverse events (irAE). We sought to determine if CTCAE classification, IBD biomarkers/endoscopic/histological scores correlate with irAE colitis outcomes. Methods A dual-centre retrospective study was performed on patients receiving ICI for melanoma, NSCLC or urothelial cancer from 2012 2018. Demographics, clinical data, endoscopies (reanalysed using Mayo/Ulcerative Colitis Endoscopic Index of...
Abstract Abiraterone acetate plus prednisolone (AAP) previously demonstrated improved survival in STAMPEDE, a multiarm, multistage platform trial men starting long‐term hormone therapy for prostate cancer. This analysis metastatic patients was planned 3 years after the first results. Standard‐of‐care (SOC) androgen deprivation therapy. The comparison randomised 1:1 to SOC‐alone with or without daily abiraterone 1000 mg + 5 (SOC AAP), continued until disease progression. primary outcome...